Wyeth mulls restructuring its global sales force

Share this article:
Wyeth said the restructuring of its U.S. sales force was only a start and that it is considering making similar changes globally.
"Obviously it is a first step. We're also looking internationally. Our European affiliates have started to look at how to optimize the sales force," Bernard Poussot, head of Wyeth's pharmaceutical operations, said in a Financial Times report.
Last month Wyeth said it would use inside, part-time sales representatives in the U.S. to complement its full-time sales force, which is being reduced by about 25% to 30%.
Adding the part-timers will result in a net sales-force reduction of about 15%, Poussot said. Wyeth has deployed part-timers in its consumer division for the past few years.
As reported in MM&M (July 2005), the drug maker began piloting part-timers in its pharmaceuticals division in July and said it will fully implement them by year's end.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.